Geroprotectors as a novel therapeutic strategy for COPD, an accelerating aging disease

Kazuhiro Ito
Thomas Colley
Nicolas Mercado

Airways Disease Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom

Abstract: Chronic obstructive pulmonary disease (COPD) progresses very slowly and the majority of patients are therefore elderly. COPD is characterized by an abnormal persistent inflammatory response to noxious environmental stimuli and there are increasing evidences for a close relationship between premature aging and chronic inflammatory diseases. Thus, COPD is considered to be a disease of an accelerating aging. In this review, we collected the evidence for roles of aging on pathogenesis of COPD and considered future therapeutic strategy for COPD based on this senescence hypothesis. Since calorie restriction has been proved to extend lifespan, many efforts were made to clarify the molecular mechanism of aging. Aging is defined as the progressive decline of homeostasis that occurs after the reproductive phase of life is complete, leading to an increasing risk of disease or death due to impaired DNA repair after damage by oxidative stress or telomere shortening as a result of repeated cell division. During aging, pulmonary function progressively deteriorates; innate immunity is impaired and pulmonary inflammation increases, accompanied by structural changes, such as an enlargement of airspaces. Noxious environmental gases, such as cigarette smoke, may worsen these aging-related events in the lung or accelerate aging of the lung due to reduction in anti-aging molecules and/or stimulation of aging molecules. Aging signaling are complex but conserved in divergent species, such as worm, fruit fly, rodent and humans. Especially the insulin like growth factor (IGF-1) signaling was well documented. Geroprotectors are therapeutics that affect the root cause of aging and age-related diseases, and thus prolong the life-span of animals. Most of geroprotectors such as melatonin, metformin, rapamycin and resveratrol are anti-oxidant or anti-aging molecule regulators. Therefore, geroprotection for the lung might be an attractive approach for the treatment of COPD by preventing premature aging of lung.

Keywords: premature aging, COPD, lung function, oxidative stress, sirtuin, geroprotector

Introduction

Globally, life expectancy is projected to increase from 68 years in 2005–2010 to 81 years in 2095–2100 according to the 2010 Revision of World Population Prospects, the official United Nation Population Projects (3rd May 2011). This is 35 years longer than that at beginning of the 20th century (46 years). Therefore, an increase in incidence of age-associated diseases such as Alzheimer’s disease, cataract, rheumatoid arthritis, osteoporosis and cardiovascular disease will have a profound public health impact. Aging is a complex, universal condition leading to the functional decline of all cells and organisms, and to major global public health problems.

Chronic obstructive pulmonary disease (COPD) is one of the well-known age-associated diseases and a major and increasing global health problem with
enormous amount of expenditure of indirect/direct health care costs. There is still a fundamental lack of knowledge about the cellular, molecular and genetic causes of COPD. Therefore, current therapies are inadequate and no treatments reduce disease progression or mortality. The pathological characteristics of COPD are chronic inflammation of peripheral and central airways, an increase in mucus producing cells and destruction of the lung parenchyma (emphysema). Airflow limitation measured by reduced forced expiratory volume in 1 second (FEV₁) progresses very slowly over several decades, and therefore most patients with symptomatic COPD are in late middle age or elderly. Thus, the incidence of COPD increases with age, suggesting an intimate relationship between the pathogenesis of COPD and aging.

COPD as an accelerating aging disease
As the prevalence is reported to be two to three times higher in the elderly (persons over 60 years of age), therefore, COPD is known as an aging associated disease. The evidence for the role of accelerated aging in COPD progression is growing and senescence is one of possible molecular pathways for development of COPD.

Physiological or molecular change with aging
The well-known epidemiological studies by Fletcher and Peto demonstrated an accelerated decline in lung function with time, with a loss of 20 mL per year, in healthy subjects with aging as well as COPD. The decline of lung function in COPD with aging were also confirmed time to time and the results were recently summarized. In addition to the lung function decline with age, a dilatation of alveoli with an enlargement of airspaces and a decrease in gas exchange surface area with a loss of supporting tissue for peripheral airways were seen and called “senile emphysema”. This results in increased residual volume and functional residual capacity due to decreased static elastic recoils of the lung. Although the total lung capacity remains constant, vital capacity is reduced and functional residual capacity is increased with aging. Expiratory flows decrease with a characteristic alteration in the flow-volume curve suggesting small airway disease. Furthermore, respiratory muscle strength is also decreased with aging.

It is also reported that the immune system (T cell and B cell) is impaired with aging, which is called immunosenescence. This results in an increased susceptibility to infection by bacteria and virus. However, the number of neutrophils in the lower respiratory tract of healthy elderly individuals is increased with an increased release of neutrophil elastase. This could contribute to the loss of elastic recoil and elastin fibers in the aging lung, resulting in deterioration of lung function.

Aging is a complex, heterogeneous, and multifactorial phenomenon, which is the consequence of multiple interactions between genes and environment. Senescence or aging is defined as the progressive decline of homeostasis that occurs after the reproductive phase of life is complete, leading to an increasing risk of disease or death. Underlying the aging process is a lifelong, bottom-up accumulation of molecular damage. Kirkwood also hypothesized that inflammatory and anti-inflammatory factors can play a part in shaping the outcomes of the aging process because cellular defects often cause inflammatory reactions, which can themselves exacerbate existing damage. Thus, aging is also considered as an inflammatory event. At molecular level, aging is the results of failure of reactive oxygen species (ROS) elimination, failure of repair of damaged DNA and telomere shortening as shown below.

Harman demonstrated that aging, senescence or age-related changes is accelerated under the influence of oxidative stress (reactive oxygen species: ROS), formed during normal oxygen metabolism. This hypothesis is called “the free radical theory of aging” and has later been extensively supported by numerous in vivo and in vitro studies. This oxidative stress causes DNA damage and increases risk of cancer. Thus, the capacity for DNA repair may be an important determinant of the rate of aging at the cell and molecular level as Promislow reported a general relationship between longevity and DNA repair. The molecules responsible for DNA repair are DNA-dependent protein kinase (DNA-PK) and Ku86 (or Ku80). DNA-PK KO mice showed telomere shortening and intestinal atrophy, which are seen as aging phenotypes. Ku86 KO mice also showed the early onset of age-specific changes characteristic of senescence in mice.

Increased production of oxygen-derived free radicals and reduced anti-oxidant capacity seen in aging are a primary driving force for inflammaging and redox-sensitive transcriptional factors, such as activator protein(AP)-1 and nuclear factor-κB (NF-κB), which switch on multiple genes encoding pro-inflammatory molecules. Especially, increased NF-κB activity during aging is due to hyperphosphorylation of 1xβ (inhibitory kappa B alpha). STAT3 and STAT 5, which are downstream of IL-6 signaling, were upregulated in T-cells from elderly subjects. As the results, increased levels of interleukin(IL)-1β, IL-6, IL-8, IL-18, IL-1ra and tumor
necrosis factor-α (TNFα) were found in plasma, serum and mononuclear blood cell culture from elderly subjects. Redox-sensitive Cyclo-oxygenase (COX), an enzyme responsible for prostaglandin (PG) synthesis, is increased with aging. This PG synthesis pathway contributes to ROS accumulation during aging in a vicious circle.

In many human somatic tissues and cells such as fibroblasts, there is a decline in cellular division capacity with age or a limited division potential before undergoing so-called “replicative senescence.” This appears to be linked to the fact that the telomeres, which protect the ends of chromosomes, get progressively shorter as cells divide. Oxidative stress has been found to have an even bigger effect on the rate of telomere loss, and telomere shortening is greatly accelerated (or slowed) in cells with increased (or reduced) levels of oxidative stress.

In the last decade, a lot of anti-aging molecules have been identified and the dysfunction and reduction of anti-aging molecules are one of the causes of progressive aging. Sirtuins are well documented anti-aging molecules. Seven molecules have been identified in the human sirtuin family (SIRT1–SIRT7) and they are known to be NAD+ dependent histone/protein deacetylases which are involved in gene expression, cell cycle regulation, apoptosis, metabolism, DNA repair and senescence. Especially, SIRT6 KO mice are reported to show aging phenotype by chromatin instability. As well as sirtuins (Type III HDAC), HDAC2 (a type I HDAC) is also reported to be an anti-aging molecule as knock-down of HDAC2 induces cellular senescence by enhancing p53-dependent trans-repression and trans-activation of a subset of target genes. FOXO transcription factor belongs to the large Forkhead family of proteins, a family of transcriptional regulators characterized by a conserved DNA-binding domain termed the ‘forkhead box’. They are important transcriptional factors for DNA repair and production of anti-oxidants, such as Mn SOD and catalase. Recently, genetic ablation of FoxO3 was reported to lead to pulmonary emphysema and exaggerated inflammatory response in lungs of mice exposed to cigarette smoke. Targeted disruption of FoxO3 also resulted in down-regulation of antioxidant genes in mouse lungs in response to cigarette smoke exposure. Thus, FoxO3 plays a pivotal role in regulation of lung inflammatory response and antioxidant genes.

Homozygous mutant klotho (KL−/−) mice exhibit premature aging with a short life span and develop air space enlargement as well as some other aging phenotypes, such as arteriosclerosis, osteoporosis, skin atrophy, and ectopic calcifications. Fractal analysis suggested that the enlarged alveoli were homogenous, a result compatible with aged lung, but not with emphysema. The secreted Klotho protein can regulate multiple growth factor signaling pathways, including insulin/IGF-1 and Wnt, and the activity of multiple ion channels. Senescence marker protein-30 (SMP30), a 34-kD protein originally identified from the rat liver, is a novel molecule that decreases with age in an androgen-independent manner. The SMP30 knockout (SMP30Y−/−) mouse has shorter life span and also developed senile lung with age-related airspace enlargement and enhanced susceptibility to harmful stimuli. Cigarette smoke exposure generates marked airspace enlargement with significant parenchymal destruction in the SMP30Y−/− mice. SMP30 was recently identified as a key enzyme (gluconolactonase) involved in the production of vitamin C and complete depletion of Vitamin C causes development of emphysema.

Evidences of COPD to be an accelerating aging disease

The classical epidemiological studies of Fletcher and Peto demonstrated that death and disability from COPD were related to an accelerated decline in lung function with time, with a loss of 50–100 mL in forced expiratory volume in 1 second (FEV1) per year, and the decline was much quicker than normal aged lung in non-smokers and smokers. Recently, Vestbo and colleagues demonstrated that the mean decrease in FEV1 per year in COPD patients was lower than in the Fletcher and Peto study. This might be one of the evidences underlying the accelerated lung aging process resulting from a failure of lung maintenance and repair due to significant and sustained lung injury by exposed noxious gases such as cigarette smoke. Functionally, vital capacity and respiratory muscle strength were reduced in COPD as well as with aging. Although air space enlargement was also observed in aged lung (senile lung), Fukuchi mentioned that aging dependent airway enlargement was different from emphysema in COPD. Premature aging might not be the direct cause of emphysema, but enhance the susceptibility of the lung to extrinsic insults including tobacco smoke from the evidence in anti-aging molecules (Klotho or SM30) deficient mice. Patel et al reported a good correlation between COPD and skin wrinkle, and this age-dependent loss of elastin fibers in lung is similar to the loss of skin elasticity and wrinkling of the skin that occurs with age. Aoshiba and Nagai reported that pulmonary emphysematous lesions appeared to be a dynamic phenomenon that involved not only the gradual loss of alveolar structure but also apoptosis, cellular proliferation, and cellular senescence. They mentioned...
that cellular proliferation compensated for increased alveolar cell apoptosis in patients with COPD, and this caused accelerating alveolar cell senescence, thereby preventing cellular proliferation and tipping the balance toward apoptosis. This, in turn, promotes the formation of emphysematous lesions.

In addition, cellular senescence is believed to induce inflammation or immuno-modulation in COPD. Lymphocyte senescence may induce an autoimmune reaction, a reduction in the adaptive immune response and possibly an increase susceptibility to infection. Particularly, lymphocytes may age more rapidly in the lungs of patients with COPD. There is an age-dependent decline in naïve T cells with oligoclonal expansion of CD8(+) CD28(null) T cells from chronic antigenic stimulation. The increase in CD8(+) CD28 (null) T regulatory cells inhibits antigen-specific CD4(+) T cell responses, leading to a decline in adaptive immune response. To compensate for the decline in the adaptive immune function there is a paradoxical up-regulation of innate immune system resulting in a proinflammatory state. The dysregulated adaptive immune system with activated innate immune responses seen with aging results in recruitment and retention of neutrophils, macrophages, and CD4(+) and CD8(+) T cells in the lungs of smokers with COPD. Once the inflammation is triggered, there is a self-perpetuating cascade of inflammation and lung parenchymal damage. Clara cells may also age more rapidly in the lungs of patients with COPD and Clara cell senescence may impair airway regeneration as well as sustain airway inflammation. Tsuji and colleagues demonstrated that alveolar cell senescence exacerbated pulmonary inflammation in patients with COPD. The lung tissue of the COPD patients contained higher percentages of proinflammatory senescent type II cells that co-expressed p16(INK4a) and phosphorylated NF-kB than the tissue from asymptomatic smokers and asymptomatic non-smokers.

As suggested in “the free radical theory of aging” by Harman, ROS accounts for progressive deleterious changes called aging or senescence. There is accumulating evidence that oxidative stress plays an important role in pathogenesis of COPD, with increased expression of oxidative stress markers in patients with COPD both systemically and in disease lung. DNA damage is induced by oxidative stress and cigarette smoke and these are risk factors for carcinogenesis. In fact, patients with COPD have an increased risk of lung cancer. This suggests that cellular senescence could also explain the significantly increased rate of lung cancers in emphysematous patients by DNA damage. Anti-oxidant enzyme and activity are also decreased in COPD as seen in aging. SOD enzyme activity is reported to be lower in chronic healthy smokers and in stable COPD patients than in healthy adults. Furthermore, ferric reducing antioxidant power (FRAP) was lower in COPD patients and it had a positive correlation with the severity of airways obstruction (FEV, % predicted). Anti-oxidant transcription factor, Nrf2, was also down-regulated in COPD.

Furthermore, expressions of anti-aging molecules are reduced in COPD. We already reported that SIRT1 was selectively reduced in lung tissue and PBMCs from COPD in agreement with a recent report. We also showed moderate reduction of SIRT6 expression in COPD lung. SIRT6 is a nuclear, chromatin-associated protein that promotes resistance to DNA damage and SIRT6 loss led to abnormalities in mice that overlapped with aging-associated degenerative processes. It is unknown whether SIRT6-deficient mice develop emphysema or not (with or without smoke exposure), and further studies are required. We also have shown that HDAC2 activity and expression were markedly reduced in COPD in peripheral lung tissue and alveolar macrophages, especially in more severe disease and that this reduction was involved in enhancing inflammation and corticosteroid insensitivity. Furthermore, preliminary studies have found that Klotho and SMP-30 levels were decreased in COPD lung (unpublished data).

In addition, there are evidences that COPD lungs have shortened telomeres as compared with age-matched non-smokers’ lungs. Telomere length was recently demonstrated to be significantly shorter in the patients with emphysema than in the asymptomatic non-smokers that in alveolar type II cells and endothelial cells, circulating leukocytes, PBMCs and fibroblasts.

Aging signaling

Although the underlying mechanisms of aging or longevity are not fully understood, it is known that disruption of the insulin/insulin-like growth factor I (IGF-I) signaling cascade can significantly extend life span in diverse species, including yeast, worms, fruit flies, and rodents. IGF-I is a potent anabolic hormone that increases cellular metabolism, enhances the function of numerous tissues, and participates in glucose homeostasis. The long-lived mutants showed reduced insulin signaling and IGF-I plasma levels, and enhanced sensitivity to insulin as well as reduced oxidative damage of macromolecules and increased stress resistance. This fundamental mechanism of aging may be evolutionarily conserved from yeast to mammals (Figure 1).

The involvement of the insulin/IGF-I-signaling pathway to aging or longevity was first demonstrated in invertebrates.
A decrease in insulin/IGF-I signaling has also been shown to extend longevity in mice. Analysis of various transgenic and knockout rodent models, characterized by shortening or extension of the life span. In humans, insulin sensitivity normally declines during aging, and insulin resistance is an important risk factor associated with hypertension, atherosclerosis and obesity, which are affecting morbidity, disability, and mortality among the elderly. Polymorphic variants of IGF-I receptor (IGF-IR) and phosphatidylinositol 3-kinase (PI3K) genes affect IGF-I plasma levels and human longevity.

Oxidative stress shares the same signaling with IGF-I. There are a lot of evidence that oxidative stress stimulated PI3K signaling, and chronic or high level of oxidative stress exposure impaired FOXO and Nrf2 responses via defects of HDAC2 and sirtuins (Figure 2). AMPK is activated under oxidative stress, but chronic exposure of oxidative stress reduces AMPK activity in lung epithelial cells (data not shown). Further studies are required to clarify the mechanism of this defect. mTOR (TORC1) is also activated as a consequence of PI3K activation.

**Potential geroprotectors**

Geroprotectors are therapeutics that affect the root cause of aging and age-related diseases, and thus slow down the aging process. These have a potential to improve age-associated disease such as COPD. Calorie restriction is the best researched method to extend longevity in mice.
intervention in aging in diverse species from yeast to primate. Most of geroprotectors might mimic calorie restriction. Greater understanding of the molecular mechanisms of aging has revealed several novel targets for anti-aging drugs/geroprotectors although the information about the effects of those drugs in the respiratory system is still limited (Table 1).

**Metformin**

Metformin (N,N-dimethylbiguanide) is an anti-glycemic, biguanide class drug used in the treatment of diabetes mellitus and polycystic ovarian syndrome. Several studies have shown that metformin can slow down the rate of aging, and decrease glucose, insulin and IGF-1 level. Thus Metformin has been described as a geroprotector.66

Anisimov and colleagues recently showed that metformin treatment increased mean life span by up to 14% and postponed tumors in female SHR mice when treated early in life.67 They also showed that metformin (100 mg/kg) increased the mean life span by 8% and maximum life span by 13.1% of HER-2/neu mice.68 In addition, metformin increased the mean life span by 8%, maximum life span by 16% in female FVB/N mice. The mechanisms behind the geroprotective effect of metformin are less established, but several potential mechanisms were reported.66

AMPK (5’ AMP-activated protein kinase) is a serine/threonine protein kinase that belongs to the energy sensing kinase family, which plays a role in cellular energy homeostasis.69 In general, activation of AMPK acts to maintain cellular energy stores, switching on catabolic pathways that produce ATP, mostly by enhancing oxidative metabolism and mitochondrial biogenesis, while switching off anabolic pathways that consume ATP. Metformin has been shown to activate AMPK in several cells such as skeletal muscle, heart, endothelial and hepatocytes, leading to reduced glucose production in the liver and reduced insulin resistance in the muscle.66 In addition to cellular energy sensing function, AMPK enhances SIRT1 activity by increasing cellular NAD+ levels,70 resulting in the deacetylation and modulation of the activity of downstream SIRT1 targets that include the peroxisome proliferator-activated receptor-gamma coactivator 1alpha and the forkhead box O1 (FOXO1) and O3 (FOXO3a) transcription factors. AMPK also phosphorylates and activates FOXO (DAF16) directly in worms, resulting in an increase of anti-oxidative stress capacity. SIRT1 deacetylates FOXO proteins in response to oxidative stress, and this could result in their activation. Metformin is also reported to inhibit mTOR signaling71 via AMPK activation, and mTOR inhibition activates sirtuin. Thus, AMPK activation by metformin affects sirtuin-FOXO axis or sirtuin-mTOR signalling, resulting in extension of life span, and it possibly improves lung function and inhibits airway inflammation in the lung.

However, metformin failed to activate AMPK in lung tissue because lungs have a very low expression of OCT1, a receptor responsible for metformin uptake in cells.72 Therefore, metformin unlikely affects lung epithelial cells directly, but possibly affects other resident cells such as alveolar macrophages and immune cells. Although patients with diabetes mellitus are not at increased risk for the development of lung cancer, the use of metformin type anti-diabetes drugs considerably decreased the risk.73 As diabetes mellitus and metabolic syndrome are common in patients with COPD,74 metformin might affect comorbidity of COPD and improve symptom systemically.

### Table 1 Potential geroprotectors and their mode of actions

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mode of action</th>
<th>Life-span extension</th>
<th>Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metformin</td>
<td>AMPK activation, SIRT1 activation, mTOR inhibition, Anti-oxidant</td>
<td>Yeast, C. elegans, Drosophila, Mouse</td>
<td>Others</td>
</tr>
<tr>
<td>Melatonin</td>
<td>Hormone, Anti-oxidant, Anti-inflammatory</td>
<td>C. elegans, Drosophila, Mouse, Rat</td>
<td>8-Isoprostane ↓, Improved dysnea in COPD</td>
</tr>
<tr>
<td>Rapamycin</td>
<td>mTOR inhibition</td>
<td>Yeast, C. elegans, Drosophila, Mouse, Rat</td>
<td></td>
</tr>
<tr>
<td>Resveratrol</td>
<td>Anti-oxidant, SIRT activation, AMPK activation, PI3K inhibition</td>
<td>Yeast, C. elegans, Drosophila, Fish, Mouse</td>
<td>Inhibition of cytokine release in alveolar macrophages from COPD</td>
</tr>
<tr>
<td>Lower dose Theophylline</td>
<td>PI3Kδ inhibition, PPAR inhibition</td>
<td>Fish, Mice</td>
<td>Low dose theophylline improved lung function in COPD</td>
</tr>
<tr>
<td>SRT2172</td>
<td>SIRT1 activation</td>
<td></td>
<td>Inhibition of MMP9, IL-8, neutrophilia in smoking mice</td>
</tr>
<tr>
<td>Sulforaphane</td>
<td>Nrf2 activation</td>
<td>Drosophila</td>
<td>Reversed steroid insensitivity in alveolar macrophage from COPD</td>
</tr>
</tbody>
</table>

**Melatonin**

Melatonin, 1-acetyl-5-methoxytryptamine, is a naturally occurring compound found in animals, plants, and microbes. The pineal indole hormone melatonin is involved
in the circadian rhythms (the sleep-wake cycle) of several biological functions through activation of melatonin receptors. Besides its function, melatonin is also known to exert a powerful antioxidant activity. Melatonin is a direct scavenger of OH, O$_2^-$, and NO.$^{75}$

The effect of melatonin on the life-span of mice, rats and fruit flies has been studied using various approaches. Izmaylov and Obukhora demonstrated that melatonin extended life span of Drosophila melanogaster possibly due to an anti-oxidant mechanism.$^{85}$ Melatonin also increased life-span of female CBA mice.$^{76}$ Furthermore, prolonged life-span by long-term administration of melatonin have been observed in SHR,$^{77}$ SAM and transgenic HER-2/neu mice. Sharman and colleagues reported that melatonin treatment reversed the change in expression of 13 genes in the cerebral cortex of elderly B6C3F1 male compared with younger mice.$^{78}$ Furthermore, melatonin treatment also increased survival of male and female rats. However at the same time, melatonin increased tumor incidence in the mice. Melatonin alone turned out neither toxic nor mutagenic in the Ames test but revealed clastogenic activity at high concentration in the COMET assay.$^{79}$ On the other hand, melatonin inhibited mutagenesis and clastogenic effects of a number of indirect chemical mutagens. The genotox mechanism should be explored more before conducting a long term clinical trial.

In bronchial asthma and COPD, melatonin level in serum was decreased during exacerbation with an increase in oxidative stress and a decrease in anti-oxidant enzymes.$^{80}$ Melatonin has been tested for COPD. In a randomized, double-blind, placebo-controlled study on the effects of melatonin in COPD,$^{81}$ thirty-six consecutive patients with clinically stable moderate to very severe COPD (30 men; mean ± SD = 66.6 ± 7.8 y) were recruited and treated with 3 mg melatonin (N = 18) or placebo for 3 months. Oxidative stress was evaluated by 8-isoprostane levels in exhaled breath condensate at baseline and after one, two and three months of treatment. In addition, IL-8 levels in exhaled breath condensate, dyspnea severity (Medical Research Council scale), lung function (spirometry), and functional exercise capacity (six min walk test) were compared at baseline and after treatment. Patients receiving melatonin showed a decrease in 8-isoprostane with significant improvement of dyspnea, although there were no significant changes in lung function or exercise capacity. The patients given melatonin did not show an increase in IL-8 ($P = 0.03$) over 3 months. Further studies are necessary to determine the potential role for melatonin in the long-term management of these patients.

As well as its anti-oxidant mechanism, recently melatonin is shown to activate SIRT1 in primary neurons of young animals, as well as in aged neurons of a murine model of senescence. Rodella et al demonstrated that SIRT1 was decreased in apolipoprotein E (APOE)-deficient mice with age, and melatonin treatment clearly restored the SIRT1 level.$^{82}$ SIRT1-p53-eNOS axis is one of the important markers of advanced vascular dysfunctions linked to aging and melatonin could reverse the defect. Melatonin was also reported to suppress production of IL-8$^{83}$ and matrix metalloproteinase-9.$^{84}$

**Resveratrol**

Resveratrol (3,4′,5-trihydroxystilbene) the plant polyphenol, is found in various plants, including grapes, berries and peanuts. It is also present in wines, especially red wines.$^{85}$ Studies showed that resveratrol extended the life-span of yeast, worms, flies, fish and mice. Resveratrol appears to mediate these effects partly by activating SIRT1, a deacetylase enzyme.$^{86}$ Resveratrol is also reported to be a powerful anti-oxidant$^{87}$ as well as a PI3K inhibitor.$^{87}$ Recently, Dallaire and Marette demonstrated that resveratrol inhibited inducible nitric oxide synthase in skeletal muscle by AMPK activation rather than SIRT1 activation.$^{88}$ As we described above, AMPK activator also leads to SIRT1 activation. Thus resveratrol affects AMPK-SIRT1 axis and showed anti-aging effects. In addition, there are a lot of evidences of anti-inflammatory effects of resveratrol in lung cells.$^{89}$

**PI3K inhibitors**

In *C. elegans*, age-1 (human PI3K homolog) mutant showed longer life, suggesting that PI3K inhibition extends life span. In fact, a pan PI3K inhibitor, LY294002 (2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) at higher concentrations significantly resulted in a small, but significant, increase in life-span.$^{90}$ It is also reported that LY294002 extended life-span of D. melanogaster.$^{91}$

We previously demonstrated that PI3Kδ was upregulated in peripheral lung of COPD and it is involved in corticosteroid resistance.$^{92}$ None of PI3Kδ inhibitors is available in clinic, but theophylline is known to exert functional PI3Kδ inhibition at lower dose. When low dose theophylline was used with steroid, it showed better efficacy in asthma and COPD than steroid alone. In the in vitro and in vivo studies, PI3Kδ inhibition enhanced steroid action.$^{92}$ Theophylline reversed defect of HDAC activity via PI3Kδ inhibition. As HDAC2 is known as anti-aging molecule, theophylline is a kind of anti-aging agent. Theophylline is also reported to
inhibit NAD+ consumption by PARP-1 activation and may therefore restore SIRT1 activity reduced under oxidative stress.

**mTOR inhibitor**

Mammalian target of rapamycin (mTOR) is a serine/threonine kinase in the phosphoinositide 3-kinase (PI3K)-related kinase family. mTOR forms two distinct protein complexes including TORC1 and TORC2, with distinct cellular functions. TORC1 regulates translation initiation and elongation, ribosome biogenesis, cell-cycle progression, lipid synthesis, mitochondrial biogenesis and autophagy. Knockdown of mTOR by RNA interference has been shown to extend the life span of worm and fruit fly. mTOR phosphorylates insulin receptor substrate 1 (IRS-1), causing insulin resistance by inhibition of insulin signalling. TORC1 also inhibits autophagy and accelerates protein synthesis. Therefore, inhibition of mTOR leads to geroprotection.

Rapamycin (Sirolimus) is an immunosuppressive agent used to prevent rejection in transplantation patients. This inhibits TORC1 and this inhibition extended the life span of yeast, C. elegans, Drosophila and mice. Very interestingly, the effect of mTOR inhibition is sex dependent, and rapamycin showed more moderate increase in life span in male rather than female in flies and mice. However, rapamycin showed immunosuppressive action by an anti-proliferative effect on clonal expansion of activated lymphocytes. Long term trial of rapamycin has not been conducted in COPD.

**SIRT activator**

Sirtuins are anti-aging molecules and control oxidative stress resistance, DNA repair and inflammation as described above. Sirtuin activation extended life span in worms by activation of autophagy and SIRT1 is required for the autophagic response to nutrient deprivation. In addition, SIRT1 negatively regulated MMP9 synthesis and SIRT1 knockdown by RNA interference enhanced MMP9 synthesis and activation. In fact, SIRT1 mRNA and protein expression are reduced in peripheral lung and alveolar macrophages of patients with COPD. Even more importantly (therapeutically), SIRT1 overexpression inhibited MMP9 expression stimulated by LPS in U937 cells.

As described as previous page, Resveratrol is known as a sirtuin activator although the molecular mechanism is controversial. Recently a SIRT1-specific activator that is 1000 more potent than resveratrol has been developed and examined as a possible therapy for diabetics. SRT2172 is one of the potent sirtuin activators. In sub-chronic smoking mice, SIRT1 activity in lung was decreased but SRT2172 intra-nasal treatment reversed this reduction. Exercise tolerance was impaired and oxygen saturation, as well as SPO2 level, after exercise was lowered in the smoking mice, but SRT2172 treatment restored exercise tolerance and SPO2 level as we previously reported (Figure 3). Thus, SIRT1 activators are promising agents for the treatment of COPD in future.

**Nrf2 activator**

From the oxidative stress/aging theory and the fact that oxidative stress is a major risk factor of COPD, anti-oxidants are likely to be effective anti-aging and COPD drugs. Currently available antioxidants, such as N-acetyl cysteine, are not very potent and may not sufficiently reduce oxidative stress in the lungs. Although some new anti-oxidants such as glutathione and superoxide dismutase analogs have been developed, novel and more effective antioxidants are required. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a cap’n’collar family member redox-sensitive transcription factor that induces endogenous anti-oxidant molecules such as the phase II anti-oxidant genes, which includes glutathione peroxidase (GPx), glutathione-S-transferase (GST), and stress-response genes, such as heme oxygenase-1 (HO-1), conferring cytoprotection against oxidative stress. Therefore this is a potential target to increase anti-oxidant activity.

As previously reported, Nrf2 function is impaired in COPD. For example, whole lung tissue and alveolar macrophages from emphysema patients were reported to show a decreased Nrf2 expression and anti-oxidant genes due to increased Keap1 and Bach1. Another study on lung homogenates from patients with COPD found that defective Nrf2 expression was due to decreased expression of its positive regulator DJ-1. We found that HDAC2 reduction by cigarette smoke exposure caused hyperacetylation of Nrf2, resulting in defect of Nrf2 induction. There are a lot of candidates as Nrf2 activators. Sulforaphane, which is extracted from broccoli, is reported as a Nrf2 activator. Malhotra and colleagues recently demonstrated that treatment with sulforaphane stimulated Nrf2, resulting in denitrosylation of HDAC2 and restoration of steroid sensitivity in alveolar macrophages from patients with COPD. Thus, sulforaphane, by activating Nrf2, is a novel therapy for reversing corticosteroid resistance in COPD and other corticosteroid-resistant inflammatory diseases.
Conclusion and future directions
COPD is one of the most prevalent chronic inflammatory diseases in elderly worldwide. Loss of working generation and disabilities associated with COPD should require urgent awareness by government, physicians and scientists, and new treatment strategy should be considered as current therapy is not useful to stop the progression of COPD. The role of accelerated aging in COPD progression is now strongly supported by numerous recent studies. In addition, aging signal cascade research has been expanded from worm and fruit fly to mammals or humans, and several molecules have been identified as the target of anti-aging drugs. Thus, geroprotection or anti-aging therapy will be the novel and attractive strategy to treat age associated inflammatory diseases or to increase quality of life in elderly patients. For this purpose, geroprotectors will be not used to extend life-span but used to prevent premature aging of the lung by exposure of oxidants. The information of effects of geroprotectors on lung aging or respiratory diseases is still limited and further investigations will be required to clarify whether those drugs are able to modify the course of COPD.

Acknowledgments
We regret that owing to space constraints we were not able to cite all the important original publications and apologies to those authors whose work we have not cited.

Disclosure
Kazuhiro Ito is currently an employee of RespiVert Ltd, and has on honorary contract with Imperial College. None of the authors has any financial relationship with a commercial entity that has an interest in the subject of this manuscript.
References


